NCT00326963View on ClinicalTrials.gov

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

PHASE4CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

May 31, 2007

Conditions
HIV Infections
Interventions
DRUG

Background ARVs

As prescribed

DRUG

PI

As prescribed

DRUG

enfuvirtide [Fuzeon]

90mg sc bid

Trial Locations (38)

2010

Sydney

2170

Liverpool

3053

Carlton

3141

South Yarra

3181

Melbourne

4000

Brisbane

10003

New York

10032

New York

12208

Albany

19107

Philadelphia

20009

Washington D.C.

21201

Baltimore

22003

Annandale

23666

Hampton

28078

Huntersville

30033

Decatur

31201

Macon

32803

Orlando

33334

Fort Lauderdale

34952

Port Saint Lucie

63139

St Louis

75246

Dallas

76104

Fort Worth

77004

Houston

77098

Houston

85006

Phoenix

90027

Los Angeles

90028

Los Angeles

90036

Los Angeles

90210

Beverly Hills

91356

Tarzana

93301

Bakersfield

94114

San Francisco

94305

Stanford

06851

Norwalk

07102

Newark

08244

Somers Point

97209-2534

Portland

Sponsors

Collaborators (1)

Trimeris
All Listed Sponsors
collaborator

Trimeris

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00326963 - BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. | Biotech Hunter | Biotech Hunter